Ipamorelin: research overview

The short version

Ipamorelin is a synthetic pentapeptide — five amino acids long — that acts as a selective agonist of the ghrelin receptor (GHS-R1a) on pituitary cells. When it binds that receptor, it triggers a pulse of growth hormone (GH) release. What makes ipamorelin different from earlier growth-hormone-releasing peptides is selectivity: even at doses far above the level needed to release GH, it does not meaningfully raise cortisol or prolactin. That narrow action profile is what earned it the description 'the first selective growth hormone secretagogue' in its founding 1998 paper ^[11].

Despite years of research, ipamorelin has never been approved as a drug anywhere. Its only published Phase 2 randomized controlled trial — testing it for postoperative bowel slowdown after surgery — missed its primary endpoint ^[8]. It exists in research and wellness contexts as an unapproved peptide sold for laboratory use only.

This page covers the published evidence. It does not recommend, prescribe, or suggest a human dose.

What it is

Ipamorelin's full sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, where Aib (alpha-aminoisobutyric acid) replaces the typical glycine at position 1, and the middle two amino acids include D-forms (mirror-image versions of natural amino acids). These substitutions make the peptide more resistant to enzyme breakdown than earlier GHRPs. Its common research names include NNC 26-0161 and NNC-26-0161 (the original Novo Nordisk code name) and ipamorelin acetate.

Ipamorelin belongs to the family of growth hormone secretagogues (GHS), which stimulate GH release by activating the ghrelin receptor rather than through the separate growth-hormone-releasing hormone (GHRH) pathway. That distinction matters: because the two pathways are independent, a GHS like ipamorelin and a GHRH analogue can act together — which is why ipamorelin is often studied alongside CJC-1295 in preclinical work ^[12]. The combination protocol has some animal-model support; it has not been tested in human efficacy trials as a pair.

Ipamorelin is not the same compound as the combination blend sometimes called 'CJC-1295/ipamorelin.' Ipamorelin is a single peptide. Whether any given research product contains only ipamorelin or a premixed blend is a formulation question, not a pharmacology one.

How it works

When ipamorelin enters the bloodstream, it binds the GHS-R1a receptor on somatotroph cells in the anterior pituitary gland. That binding triggers a surge in intracellular calcium and activates the adenylyl cyclase / protein kinase A (PKA) pathway, leading to secretion of stored GH in a discrete pulse. In healthy male volunteers given intravenous ipamorelin, the GH response peaked around 40 minutes after dosing — a single, clear pulse ^[9].

The mechanism has several important features worth keeping straight:

• GH selectivity. In the original characterization in rats and swine, ipamorelin released GH comparably to GHRP-6 — but even at doses more than 200-fold higher than its GH threshold, it did not meaningfully raise ACTH or cortisol ^[11]. This sets it apart from GHRP-2 and GHRP-6, which raise cortisol noticeably. The adrenocortical-sparing effect is a specific, measured property, not a marketing claim.
• Short half-life. Population pharmacokinetic modeling in humans found a terminal half-life of approximately 2 hours, with a small distribution volume (0.22 L/kg) and clearance of 0.078 L/h/kg ^[9]. The peptide does not accumulate over days the way some longer-acting compounds do.
• Pancreatic and orexigenic effects. GHS-R1a receptors are expressed in tissues beyond the pituitary, including pancreatic islet cells and hypothalamic appetite circuits. Ipamorelin has been shown in preclinical work to stimulate insulin release from isolated pancreatic tissue and to promote appetite and fat deposition through central ghrelin-receptor signaling — effects that are separate from GH and that matter for certain safety considerations ^[7].
• Bone growth (preclinical). In adult female rats given subcutaneous ipamorelin for 15 days, longitudinal bone growth rate increased dose-dependently without changing systemic IGF-1 levels — suggesting a partly local, GH-pulse-driven skeletal effect ^[10].

What the research shows

The founding science (1998). Raun et al. ^[11] characterized ipamorelin in primary rat pituitary cell cultures, anesthetized rats, and conscious swine. In pigs, the GH threshold dose (ED50) was 2.3 nmol/kg, similar to GHRP-6 at 3.9 nmol/kg. No meaningful cortisol or prolactin rise was observed even at 200× the GH threshold. This paper established ipamorelin's selectivity and is still the canonical reference.

Human pharmacokinetics (1999). Gobburu et al. ^[9] characterized ipamorelin's kinetics and GH dynamics in eight healthy male volunteers per dose level, across five intravenous infusion doses. The pharmacokinetics were dose-proportional (linear), with a terminal half-life of about 2 hours, and the GH pulse peaked at roughly 40 minutes post-dose. This is one of the only published human ipamorelin datasets and is referenced whenever the compound's human pharmacology is described.

Bone growth in rats (1999). Johansen et al. ^[10] gave adult female rats subcutaneous ipamorelin at three dose levels for 15 days and measured tibial growth-plate width as a proxy for longitudinal bone growth. Growth rate increased from 42 to 52 micrometers per day at the highest dose, with no change in circulating IGF-1 or bone-turnover markers — a locally driven GH-pulse effect.

The Phase 2 RCT (2014). Beck et al. ^[8] conducted a prospective, randomized, controlled trial (NCT00672074) of ipamorelin in 114 adults undergoing open or laparoscopic bowel resection. The primary endpoint was time to first tolerated meal. The result: 25.3 hours with ipamorelin versus 32.6 hours with placebo — a numeric difference but not statistically significant (p = 0.15). The primary endpoint was missed. Treatment-emergent adverse events were 87.5% in the ipamorelin arm versus 94.8% in placebo, with no ipamorelin-specific safety signal in this short perioperative window. This remains the only published efficacy RCT for ipamorelin in humans.

Class-level cardiovascular signal (2015). Stokes et al. ^[7] studied GSK894281 — a different GHS-R1a agonist, not ipamorelin itself — in rats for 28 days. They found dose-dependent myocardial degeneration and necrosis detectable by histopathology, with elevated heart-type fatty-acid-binding protein (FABP3) at high doses. Ipamorelin was not tested in this study, but it acts through the same receptor class. The study stands as a class-level safety signal that makes chronic GHS-R1a agonism in humans an area of ongoing uncertainty.

Chemotherapy-related weight loss (2024). Lu et al. ^[6] tested ipamorelin and anamorelin in ferrets given cisplatin. Ipamorelin (1–3 mg/kg IP) reduced cisplatin-associated body-weight loss by approximately 24% in the delayed phase but had no effect on the nausea and vomiting that cisplatin causes — a peripheral weight-preservation mechanism with no anti-emetic activity. Anamorelin showed central anti-emetic effects that ipamorelin lacked.

Orthopaedic review (2026). Mayfield et al. ^[12] reviewed injectable peptide therapies for a sports-medicine audience. They noted that the CJC-1295 + ipamorelin combination improved maximal muscle tetanic tension in a mouse glucocorticoid-induced muscle-loss model, and they concluded that 'safety and dosing data remain unknown' for ipamorelin and that 'significant research on safety and efficacy is required before clinical recommendations can be made.'

Reported effects, cautions and safety

Reported effects from research-use communities (anecdotal, not clinical evidence)

The following are patterns people describe in research-use communities. They are self-reported, unverified, and not controlled observations. They do not establish that ipamorelin causes these effects.

• Deeper, more restorative sleep — consistently the most-cited benefit. Users describe falling asleep faster, sleeping more deeply, and waking more rested, with effects often appearing within one to two weeks of a pre-bedtime protocol. Anecdotal.
• Vivid dreams in early weeks — frequently reported alongside sleep improvements. Typically described as transient, settling into stable deep sleep over subsequent weeks. Anecdotal.
• Faster recovery and reduced post-training soreness — people in research-use communities describe faster bounce-back between training sessions and improved subjective tissue recovery. Anecdotal.
• Gradual leaner body composition over weeks to months — some users report a slow shift toward a leaner appearance, typically noted from weeks five to twelve. Confounded by concurrent diet and training. Anecdotal.
• Facial flushing and head-rush shortly after injection — a frequently noted transient reaction, appearing 5–15 minutes post-injection and lasting up to an hour. Anecdotal, cause unconfirmed.
• Tingling or numbness in hands and feet — transient tingling attributed by users to fluid shifts, most pronounced in the first few weeks. Anecdotal.
• Mild water retention and puffiness — some users report transient puffiness in fingers, ankles, or face, characteristically milder than with older GHRP compounds. Anecdotal.
• Increased hunger, especially in hours after injection — consistent with the ghrelin-receptor mechanism. Some users describe an unwanted appetite uptick. Anecdotal.
• Early fatigue, dizziness, or spacey feeling after injection — transient lightheadedness, especially in early weeks. Anecdotal.
• Diminishing response over months of continuous use — some users report that perceived effects seem to fade after three to four months of uninterrupted use. Anecdotal.

Cautions grounded in the published literature

• Active or recent malignancy. GH stimulates IGF-1 production, a well-characterized mitogen. Chronically raising GH-pulse amplitude is a theoretical concern in the context of pre-existing or occult tumors ^[11][10].
• Diabetes or impaired glucose tolerance. GH reduces peripheral insulin sensitivity. Ipamorelin also has a direct insulinotropic effect on pancreatic islet cells in preclinical work, creating unpredictable metabolic impact in people with insulin dysregulation. No human glycemic data exist for ipamorelin at research-use doses. ^[7]
• Cardiovascular disease, heart failure, or significant edema. GH excess raises extracellular fluid volume. A related GHS-R1a agonist produced dose-dependent myocardial degeneration in rats ^[7]. Long-term cardiovascular safety of chronic ipamorelin dosing in humans is uncharacterized.
• Appetite dysregulation or adiposity. The ghrelin-receptor mechanism is orexigenic. Preclinical data show GH-independent adiposity and leptin elevation with GHS-R1a agonism ^[7]. People for whom increased appetite or fat deposition would be clinically harmful should be aware of this class-level signal.
• Unknown long-term human safety. The only controlled human ipamorelin data are a short perioperative RCT (n=114, up to 7 days IV) ^[8] and an acute PK/PD study (n=8 per dose, IV infusion) ^[9]. No long-term human safety database exists. The dominant route in research use is subcutaneous self-administration, which has no published safety or pharmacokinetic characterization in humans.
• Anti-doping prohibition. Ipamorelin and other growth-hormone secretagogues are prohibited in sport at all times under WADA category S2. Established urine-detection methods exist.

Where it fits in the research-fundamentals map

Ipamorelin is this desk's lead compound because it sits at an instructive intersection: it is mechanistically well-characterized, it has real human pharmacokinetic data, and its Phase 2 trial outcome is the kind of honest result that matters for calibrating expectations about research peptides generally. It failed its primary endpoint in the only controlled human efficacy trial ever run. That is not a reason to dismiss it — it is simply the current state of the evidence.

In the context of this desk, ipamorelin represents the growth-hormone-axis territory of peptide research. BPC-157 covers tissue repair; Semaglutide covers the metabolic/GLP-1 axis; GHK-Cu covers copper-mediated skin and matrix biology. Compare them side by side to see where their evidence bases, regulatory positions, and research questions diverge.